{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001595248","name":"Genprex, Inc.","summary":"Genprex, Inc. is a clinical-stage gene therapy company developing gene-based therapies for cancer and diabetes. Its oncology platform uses the ONCOPREX Delivery System with lipid-based nanoparticles to deliver tumor suppressor genes intravenously. Lead oncology candidate REQORSA (quaratusugene ozeplasmid) is in clinical trials for NSCLC and SCLC. Its diabetes candidate GPX-002 uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct to treat Type 1 and Type 2 diabetes.","people":[],"products":[{"name":"REQORSA Gene Therapy (quaratusugene ozeplasmid)","type":"platform","description":"Tumor suppressor gene therapy delivered via ONCOPREX lipid nanoparticles for NSCLC and SCLC, used in combination with approved cancer drugs."},{"name":"GPX-002","type":"platform","description":"AAV vector gene therapy containing Pdx1 and MafA genes administered into the pancreatic duct for Type 1 and Type 2 diabetes."},{"name":"ONCOPREX Delivery System","type":"platform","description":"Systemic, non-viral lipid-based nanoparticle delivery system for tumor suppressor gene-expressing plasmids administered intravenously."}],"partnerships":[{"partner_name":"The University of Texas MD Anderson Cancer Center","partnership_type":"licensing","description":"Exclusive worldwide license for TUSC2 and other tumor suppressor genes on Chromosome 3; sponsored research agreement signed August 2022.","start_date":null},{"partner_name":"University of Pittsburgh","partnership_type":"licensing","description":"Exclusive worldwide license for diabetes gene therapy technologies (Pdx1, MafA genes); amended and restated license agreement February 2025.","start_date":null},{"partner_name":"AstraZeneca","partnership_type":"development","description":"Combination clinical trial (Acclaim-1) using REQORSA with AstraZeneca's Tagrisso (osimertinib) for late-stage NSCLC with EGFR mutations.","start_date":null},{"partner_name":"Merck & Co.","partnership_type":"development","description":"Combination clinical trial (Acclaim-2) using REQORSA with Keytruda (pembrolizumab) for late-stage NSCLC; enrollment ceased August 2024.","start_date":null},{"partner_name":"Genentech, Inc.","partnership_type":"development","description":"Combination clinical trial (Acclaim-3) using REQORSA with Tecentriq (atezolizumab) as maintenance therapy for extensive-stage SCLC.","start_date":null}],"affiliations":[],"origin":{"leaf":"444c17a9b846ed92764aa6c67084e0ef3332e355d1136930673f21fec2050b43","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"85adec572ea9e69094e7f1deced65ab4b5d1f5e5d5568b39a8162599a88f00c1","parent":"bd5a8b3aa7975f5ce0d921cc5c778f7c737fd9a2c545990704a02f9ab8659ef6","source":"0001437749-26-010346","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}